<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784039</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0, 25 February 2021</org_study_id>
    <nct_id>NCT04784039</nct_id>
  </id_info>
  <brief_title>D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study</brief_title>
  <acronym>CARDDI-BEL</acronym>
  <official_title>D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims at evaluating the number of thromboembolic events post cardioversion in&#xD;
      patients receiving a direct current cardioversion with either prior transesophageal&#xD;
      echocardiography or D-Dimer (DD) analysis.&#xD;
&#xD;
      Patients in need of a direct current cardioversion (DCCV), meeting the criteria for DCCV with&#xD;
      prior transesophageal echocardiography (TEE), will be asked to participate in the CARDDI-BEL&#xD;
      study.&#xD;
&#xD;
      Patients will be randomized on a 1:1 ratio to the TEE-group or DD-group. Patients in the&#xD;
      TEE-group will receive TEE prior to cardioversion to exclude left atrial thrombus according&#xD;
      to current guidelines [1]. In patients randomized to the DD-group, D-Dimer will be analyzed&#xD;
      (cut-off defined by DDage). If the DDage &gt; 10x patient's age, the analysis is suggestive for&#xD;
      the presence of left atrial thrombus and the cardioversion will be performed with prior TEE.&#xD;
      In case of negative DDage, no TEE will be used in the DD-group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence in thromboembolic events between both groups after 4 weeks follow-up</measure>
    <time_frame>up to 4 weeks after cardioversion</time_frame>
    <description>The number of thromboembolic events (stroke, transient ischemic attack, ...) in the TEE and DD-group will be compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between D-Dimer-value (ng/L) and number of thrombi visible on TEE</measure>
    <time_frame>Procedure (At time of cardioversion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DD-value (ng/L) with flow velocity (m/s) in case of spontaneous contrast or suspicion of thrombus in left atrial appendage</measure>
    <time_frame>Procedure (At time of cardioversion)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1368</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>TEE-group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DD-group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transesophageal echocardiography</intervention_name>
    <description>Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE</description>
    <arm_group_label>TEE-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>D-Dimer analysis</intervention_name>
    <description>Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion</description>
    <arm_group_label>DD-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients with non-valvular atrial fibrillation scheduled for direct current&#xD;
             cardioversion with prior TEE according to current guidelines&#xD;
&#xD;
          -  Patients willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac surgery within the previous 90 days.&#xD;
&#xD;
          -  Coronary percutaneous transluminal coronary angioplasty/stenting within the previous&#xD;
             90 days or myocardial infarction within the previous 60 days.&#xD;
&#xD;
          -  Significant congenital anomaly or other medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment&#xD;
&#xD;
          -  History of blood clotting disease or bleeding abnormalities.&#xD;
&#xD;
          -  Patients with valve implants&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Aortic aneurysm or dissection&#xD;
&#xD;
          -  Documented history of deep vein thrombosis within the last 6 months&#xD;
&#xD;
          -  Documented history of pulmonary embolism within the last 6 months&#xD;
&#xD;
          -  Unwilling or unable to provide informed consent.&#xD;
&#xD;
          -  Recent transient ischemic attack or stroke (90 days)&#xD;
&#xD;
          -  Instable angina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Knecht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien Knecht, MD, PhD</last_name>
    <phone>003250452670</phone>
    <email>sebastien.knecht@azsintjan.be</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Sebastien Knecht</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

